Triple dose of gadolinium-DTPA and delayed MRI in patients with benign multiple sclerosis

M. Filippi, R. Capra, A. Campi, B. Colombo, F. Prandini, N. Marciano, R. Gasparotti, G. Comi

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Objectives - To evaluate whether a triple dose of gadolinium-DTPA (Gd-DTPA) or delayed MRI increase the number, size, and conspicuousness of enhancing lesions in patients with benign multiple sclerosis. Methods - T1 weighted brain MRI was carried out on 20 patients with benign multiple sclerosis (expanded disability status scale <3 with a disease duration > 10 years) in two sessions. In the first session, one scan was obtained before and two scans five to seven minutes and 20-30 minutes after the injection of 0.1 mmol/kg Gd-DTPA (standard dose). In the second session, six to 24 hours later, the same procedure was repeated with 0.3 mmol/kg Gd-DTPA (triple dose). Results - Nine enhancing lesions were found in seven patients (35%) using the standard dose of Gd-DTPA. The numbers of enhancing lesions increased to 13 (P = 0.03) and the number of patients with such lesions to eight (40%) on the delayed standard dose scans. On the early triple dose scans, we found 19 enhancing lesions in 10 patients (50%). The number of enhancing lesions was significantly higher (P = 0.01) than that obtained with the early standard dose. The number of enhancing lesions was 18 and the number of 'active' patients 11 (55%) on the delayed triple dose scans. The enhancing areas increased progressively from the early standard dose scans to the delayed triple dose scans. The contrast ratios of the lesions detected in the early standard dose scans was lower than those of lesions present in the early (P = 0.01) and delayed (P = 0.04) triple dose scans. Conclusions - More enhancing lesions were detected in patients with benign Neurology multiple sclerosis with both delay of and the use of a triple dose of Gd-DTPA suggesting that the amount of inflammation in the lesions of such patients is mild and heterogeneous.

Original languageEnglish
Pages (from-to)526-530
Number of pages5
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume60
Issue number5
Publication statusPublished - May 1996

Fingerprint

Gadolinium DTPA
Multiple Sclerosis
Neurology
Inflammation
Injections
Brain

Keywords

  • Benign multiple sclerosis
  • Delayed MRI
  • Imaging
  • Magnetic resonance
  • Triple dose gadolinium-DTPA

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)
  • Neuropsychology and Physiological Psychology

Cite this

Triple dose of gadolinium-DTPA and delayed MRI in patients with benign multiple sclerosis. / Filippi, M.; Capra, R.; Campi, A.; Colombo, B.; Prandini, F.; Marciano, N.; Gasparotti, R.; Comi, G.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 60, No. 5, 05.1996, p. 526-530.

Research output: Contribution to journalArticle

Filippi, M. ; Capra, R. ; Campi, A. ; Colombo, B. ; Prandini, F. ; Marciano, N. ; Gasparotti, R. ; Comi, G. / Triple dose of gadolinium-DTPA and delayed MRI in patients with benign multiple sclerosis. In: Journal of Neurology, Neurosurgery and Psychiatry. 1996 ; Vol. 60, No. 5. pp. 526-530.
@article{8b644f6f07144bf79902f5735aefb814,
title = "Triple dose of gadolinium-DTPA and delayed MRI in patients with benign multiple sclerosis",
abstract = "Objectives - To evaluate whether a triple dose of gadolinium-DTPA (Gd-DTPA) or delayed MRI increase the number, size, and conspicuousness of enhancing lesions in patients with benign multiple sclerosis. Methods - T1 weighted brain MRI was carried out on 20 patients with benign multiple sclerosis (expanded disability status scale <3 with a disease duration > 10 years) in two sessions. In the first session, one scan was obtained before and two scans five to seven minutes and 20-30 minutes after the injection of 0.1 mmol/kg Gd-DTPA (standard dose). In the second session, six to 24 hours later, the same procedure was repeated with 0.3 mmol/kg Gd-DTPA (triple dose). Results - Nine enhancing lesions were found in seven patients (35{\%}) using the standard dose of Gd-DTPA. The numbers of enhancing lesions increased to 13 (P = 0.03) and the number of patients with such lesions to eight (40{\%}) on the delayed standard dose scans. On the early triple dose scans, we found 19 enhancing lesions in 10 patients (50{\%}). The number of enhancing lesions was significantly higher (P = 0.01) than that obtained with the early standard dose. The number of enhancing lesions was 18 and the number of 'active' patients 11 (55{\%}) on the delayed triple dose scans. The enhancing areas increased progressively from the early standard dose scans to the delayed triple dose scans. The contrast ratios of the lesions detected in the early standard dose scans was lower than those of lesions present in the early (P = 0.01) and delayed (P = 0.04) triple dose scans. Conclusions - More enhancing lesions were detected in patients with benign Neurology multiple sclerosis with both delay of and the use of a triple dose of Gd-DTPA suggesting that the amount of inflammation in the lesions of such patients is mild and heterogeneous.",
keywords = "Benign multiple sclerosis, Delayed MRI, Imaging, Magnetic resonance, Triple dose gadolinium-DTPA",
author = "M. Filippi and R. Capra and A. Campi and B. Colombo and F. Prandini and N. Marciano and R. Gasparotti and G. Comi",
year = "1996",
month = "5",
language = "English",
volume = "60",
pages = "526--530",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - Triple dose of gadolinium-DTPA and delayed MRI in patients with benign multiple sclerosis

AU - Filippi, M.

AU - Capra, R.

AU - Campi, A.

AU - Colombo, B.

AU - Prandini, F.

AU - Marciano, N.

AU - Gasparotti, R.

AU - Comi, G.

PY - 1996/5

Y1 - 1996/5

N2 - Objectives - To evaluate whether a triple dose of gadolinium-DTPA (Gd-DTPA) or delayed MRI increase the number, size, and conspicuousness of enhancing lesions in patients with benign multiple sclerosis. Methods - T1 weighted brain MRI was carried out on 20 patients with benign multiple sclerosis (expanded disability status scale <3 with a disease duration > 10 years) in two sessions. In the first session, one scan was obtained before and two scans five to seven minutes and 20-30 minutes after the injection of 0.1 mmol/kg Gd-DTPA (standard dose). In the second session, six to 24 hours later, the same procedure was repeated with 0.3 mmol/kg Gd-DTPA (triple dose). Results - Nine enhancing lesions were found in seven patients (35%) using the standard dose of Gd-DTPA. The numbers of enhancing lesions increased to 13 (P = 0.03) and the number of patients with such lesions to eight (40%) on the delayed standard dose scans. On the early triple dose scans, we found 19 enhancing lesions in 10 patients (50%). The number of enhancing lesions was significantly higher (P = 0.01) than that obtained with the early standard dose. The number of enhancing lesions was 18 and the number of 'active' patients 11 (55%) on the delayed triple dose scans. The enhancing areas increased progressively from the early standard dose scans to the delayed triple dose scans. The contrast ratios of the lesions detected in the early standard dose scans was lower than those of lesions present in the early (P = 0.01) and delayed (P = 0.04) triple dose scans. Conclusions - More enhancing lesions were detected in patients with benign Neurology multiple sclerosis with both delay of and the use of a triple dose of Gd-DTPA suggesting that the amount of inflammation in the lesions of such patients is mild and heterogeneous.

AB - Objectives - To evaluate whether a triple dose of gadolinium-DTPA (Gd-DTPA) or delayed MRI increase the number, size, and conspicuousness of enhancing lesions in patients with benign multiple sclerosis. Methods - T1 weighted brain MRI was carried out on 20 patients with benign multiple sclerosis (expanded disability status scale <3 with a disease duration > 10 years) in two sessions. In the first session, one scan was obtained before and two scans five to seven minutes and 20-30 minutes after the injection of 0.1 mmol/kg Gd-DTPA (standard dose). In the second session, six to 24 hours later, the same procedure was repeated with 0.3 mmol/kg Gd-DTPA (triple dose). Results - Nine enhancing lesions were found in seven patients (35%) using the standard dose of Gd-DTPA. The numbers of enhancing lesions increased to 13 (P = 0.03) and the number of patients with such lesions to eight (40%) on the delayed standard dose scans. On the early triple dose scans, we found 19 enhancing lesions in 10 patients (50%). The number of enhancing lesions was significantly higher (P = 0.01) than that obtained with the early standard dose. The number of enhancing lesions was 18 and the number of 'active' patients 11 (55%) on the delayed triple dose scans. The enhancing areas increased progressively from the early standard dose scans to the delayed triple dose scans. The contrast ratios of the lesions detected in the early standard dose scans was lower than those of lesions present in the early (P = 0.01) and delayed (P = 0.04) triple dose scans. Conclusions - More enhancing lesions were detected in patients with benign Neurology multiple sclerosis with both delay of and the use of a triple dose of Gd-DTPA suggesting that the amount of inflammation in the lesions of such patients is mild and heterogeneous.

KW - Benign multiple sclerosis

KW - Delayed MRI

KW - Imaging

KW - Magnetic resonance

KW - Triple dose gadolinium-DTPA

UR - http://www.scopus.com/inward/record.url?scp=0029980586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029980586&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 526

EP - 530

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 5

ER -